MedaRed is targeting a blood-clotting factor called fibrin linked to neuron-toxic inflammation in diseases including Alzheimer’s, based on the work of Katerina Akassoglou at UCSF’s School of Medicine.

Two state-run initiatives targeting publicly-funded research have awarded $17.5m to programs including University of Auckland’s commercialisation arm, as New Zealand continues its bid to bring national R&D spend to 2% of GDP over the next decade.

Armed with findings from University of Oxford's Department of Zoology, Blue Water Vaccines believes it has the blueprint for a universal influenza vaccine.

The deadline for Roche’s $4.3bn purchase of CHOP's gene therapy developer Spark has been postponed until April 2020 amid regulatory scrutiny and pending lawsuits.

Evotec has spun out Breakpoint Therapeutics and equipped the oncology drug developer with $35m in funding also backed by Taiho Pharmaceutical.

Belong.Life, the operator of a cancer-focused online support network, will use the Iqvia-led round to expand its Belong Patient Engagement Platform.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The machine learning-powered biological research startup has increased its overall funding to $20.8m following an investment from Google's Gradient Ventures unit.

Autoimmune disease drug maker Citryll has hit the first close of a targeted $19m series A, having sourced commitments from BrightGene and ModiQuest.

Keio Innovation Initiative contributed to a $20m round that increased the total funding for medical access app developer CureApp, partially based on Keio University research, to nearly $39m.